Icahn School Of Medicine At Mount Sinai

Younger Black patients with acute myeloid leukemia had worse outcomes than their white counterparts, including a higher early death rate, numerically lower complete remission rate and shorter OS, according to study results.

Treatment with venetoclax plus azacitidine conferred better outcomes than azacitidine alone among select patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit below 45% without phlebotomy, according to a study presented at ASH Annual Meeting and Exposition.

A vast majority of patients with acute myeloid leukemia and myelodysplastic syndrome converted to seropositivity after two COVID-19 vaccine doses, according to a study presented at ASH Annual Meeting and Exposition.

Supportive therapies are necessary to help ensure patients adhere to aromatase inhibitor treatment, according to study results presented at San Antonio Breast Cancer Symposium.

Race did not significantly predict response to treatment outcomes among women with high-risk breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Imaging mass cytometry appeared feasible and allowed for a more comprehensive overview of triple-negative breast cancer heterogeneity at a single-cell level, according to study results presented at San Antonio Breast Cancer Symposium.

Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

A risk score based on 8 years of data showed excellent prediction of risk for contrast-induced acute kidney injury in patients undergoing PCI, researchers reported at the American Heart Association Scientific Sessions.

Biomarkers can identify patients at high risk for diabetic kidney disease, as well as help nephrologists make early clinical decisions to slow its progression, according to a speaker at ASN Kidney Week.